Amsterdam, The Netherlands, Dec. 1, 2014 (GLOBE NEWSWIRE) -- uniQure N.V. (Nasdaq:QURE), a leader in human gene therapy, today announced results for the third quarter of 2014.
Corporate Highlights and Pipeline Program Updates
- Hemophilia B Program - uniQure is finalizing all regulatory, trial site and administrative preparations for the initiation of its Phase 1/2 clinical trial in hemophilia B. The Company expects to complete these efforts as planned by the end of 2014 and anticipates the dosing of the first patient to be announced in early 2015. The Company still expects to announce initial results in mid-2015.
- Glybera ® (alipogen tiparvovec) - uniQure’s commercialization partner Chiesi confirmed that the first commercial treatment of a LPLD patient with Glybera will occur in the last quarter of 2014/first quarter 2015.
- Collaborator-sponsored Pipeline Programs - In October, top-line results from the Phase 1 clinical trial in acute intermittent porphyria (AIP) confirmed the safety and successful transduction of patients’ liver cells with the porphobilinogen deaminase gene (PBGD) using uniQure’s proprietary AAV5 viral vector, corroborating the interim analysis presented in the second quarter of 2014.
To read full press release, please click here.
Help employers find you! Check out all the jobs and post your resume.